Their study suggests that the levels of CXCL9 and CXCL10 expression in breast cancer tissues is correlated with prognosis and tumor-infiltrating lymphocytes, which may influence immunotherapy response and also discussed the crosstalk between this axis and other immune pathways, such as the PD-1/PD-L1 axis. This evidence concerns the gene CXCL10 and breast cancer.